

**Abstract**

The invention relates to a method for diagnosing and  
5 treating Hodgkin's lymphomas (lymphogranulomatosis) which  
is based on the expression of the variant exon v10 of the  
CD44 gene as a molecular marker or target. There is a  
significant correlation between v10 expression and the  
stage and prognosis of the disease. In a preferred  
10 embodiment, v10-specific antibody molecules are used to  
measure the expression of the exon in samples. In another  
preferred embodiment, radiolabelled v10-specific  
antibodies are used to treat Hodgkin's lymphomas.